Adaptimmune Therapeutics plc Stock News

Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.

- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff -

The hunt for the next biotech buyout play is apparently underway.

Investors need to pay close attention to for Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2021 Results - Earnings Call Transcript

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and

The biotech's shares have definitely lost their shine in 2021.

With the trading day more than halfway over, the markets were moving higher going into the weekend.

A key pipeline drug performs well in a mid-stage clinical trial.

Adaptimmune Therapeutics plc (NASDAQ: ADAP) revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4). Data will be presented at

- Data will support BLA filing for afamitresgene autoleucel next year -

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS:

- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells -

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2021 Results - Earnings Call Transcript

Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q4 2020 Results - Earnings Call Transcript